{"entity":{"id":"nct07549906","kind":"trial","name":"Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospecti","aka":[],"tldr":"A phase 2 trial of capecitabine, fOLFOX (5-FU, leucovorin, oxaliplatin) and propranolol (Hemangeol) in colorectal cancer, run by Sun Yat-sen University, not yet recruiting.","summary":"Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study is a phase 2, randomised interventional study registered as NCT07549906 by Sun Yat-sen University, with a registry enrolment figure of 45 participants, started 2026-04-20 and due to reach its primary completion in 2026-07-31. Interventions recorded: Iparomlimab/Tuvonralimab; Capecitabine; Oxaliplatin; Propranolol. Conditions listed: Colon Cancer (Stage II &Amp; III); Immunotherapy; Beta Blocker; Neoadjuvant Chemoimmunotherapy. Primary outcome: Major Pathological Response (MPR). Colorectal eligibility wording from the registry: \"Diagnosis / Stage: Histologically confirmed and radiologically assessed colon adenocarcinoma that is T4, or T3 with lymph node metastasis, with tumor location ≥10 cm from the anal verge, and clinical TNM staging per AJCC/UICC 8th edition\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07549906","url":"https://clinicaltrials.gov/study/NCT07549906"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["capecitabine","folfox","propranolol-hemangeol"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07549906","phase":"2","setting":"Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study","sponsor":"Sun Yat-sen University","enrolled":45,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07549906/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"propranolol-hemangeol","kind":"drug","name":"Propranolol (Hemangeol)","route":"/drugs/propranolol-hemangeol/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}